What to Expect From AbbVie Inc. in 2018
In the words of the legendary James Brown, I feel good.
Early this year, I bought a position in AbbVie (NYSE: ABBV). The big pharma stock is on track for 2017 to be its best year ever. And I'm sitting on a nice gain of 57%, a little higher than AbbVie's year-to-date gain because of the timing of when I bought the stock.
Now that 2017 is drawing to an end, though, it's time to focus on the new year. Will AbbVie's success continue into 2018? Here's what I think investors should expect from the drugmaker next year.
Source: Fool.com
AbbVie Inc. Stock
The stock is an absolute favorite of our community with 33 Buy predictions and no Sell predictions.
As a result the target price of 181 € shows a slightly positive potential of 2.27% compared to the current price of 176.98 € for AbbVie Inc..